Abraxane + carboplatin(AstraZeneca)은 Non Small Cell Lung Cancer NSCLC 표적 치료제로, Non Small Cell Lung Cancer NSCLC 영역에서 개발·상용화 중입니다. 작용기전: Targeting the ERRα/LDHA pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 44.9% (ClinicalTrials.gov NCT01317615). 차별점: novel NK1 receptor antagonist, has been reported to possess a longer half-life than conventional drugs and demonstrates favor.
Non Small Cell Lung Cancer NSCLC
Non Small Cell Lung Cancer NSCLC
Recruiting
novel NK1 receptor antagonist, has been reported to possess a longer half-life than conventional drugs and demonstrates favor
Targeting the ERRα/LDHA pathway
Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr -Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment
biomarkers to guide patient selection and treatment adaptation are lacking
resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Abraxane + carboplatin(AstraZeneca)은 Non Small Cell Lung Cancer NSCLC 표적 치료제로, Non Small Cell Lung Cancer NSCLC 영역에서 개발·상용화 중입니다. 작용기전: Targeting the ERRα/LDHA pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 44.9% (ClinicalTrials.gov NCT01317615). 차별점: novel NK1 receptor antagonist, has been reported to possess a longer half-life than conventional drugs and demonstrates favor.
Non Small Cell Lung Cancer NSCLC
Non Small Cell Lung Cancer NSCLC
Recruiting
novel NK1 receptor antagonist, has been reported to possess a longer half-life than conventional drugs and demonstrates favor
Targeting the ERRα/LDHA pathway
Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr -Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment
biomarkers to guide patient selection and treatment adaptation are lacking
resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.